Top Markets
Coin of the day
Odyssey Therapeutics, Inc. Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc.

ODTX
株式のランク #8753
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused... Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
株価
$24.55
最終同期: 2026-08-28
時価総額
$1.18B
変化(1日)
-5.50%
変化(1年)
-
US
取引 Odyssey Therapeutics, Inc. (ODTX)

カテゴリー

Odyssey Therapeutics, Inc.(ODTX)の配当利回りの履歴
Odyssey Therapeutics, Inc.(銘柄コード: ODTX)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Odyssey Therapeutics, Inc.(ODTX)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)